Arguments in favour of remdesivir for treating SARS-CoV-2 infections
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
International journal of antimicrobial agents - 55(2020), 4 vom: 01. Apr., Seite 105933 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ko, Wen-Chien [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2020 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijantimicag.2020.105933 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307358992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307358992 | ||
| 003 | DE-627 | ||
| 005 | 20231225125406.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijantimicag.2020.105933 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1024.xml |
| 035 | |a (DE-627)NLM307358992 | ||
| 035 | |a (NLM)32147516 | ||
| 035 | |a (PII)S0924-8579(20)30083-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ko, Wen-Chien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arguments in favour of remdesivir for treating SARS-CoV-2 infections |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Betacoronavirus | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Wuhan pneumonia | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a DNA-Directed RNA Polymerases |2 NLM | |
| 650 | 7 | |a EC 2.7.7.6 |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Rolain, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Nan-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Po-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ching-Tai |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Ping-Ing |e verfasserin |4 aut | |
| 700 | 1 | |a Hsueh, Po-Ren |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of antimicrobial agents |d 1991 |g 55(2020), 4 vom: 01. Apr., Seite 105933 |w (DE-627)NLM090678974 |x 1872-7913 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2020 |g number:4 |g day:01 |g month:04 |g pages:105933 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijantimicag.2020.105933 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2020 |e 4 |b 01 |c 04 |h 105933 | ||